Researchers at the University of Michigan College of Pharmacy have developed a nanoparticle that alters the gut microbiome and alleviates symptoms of inflammatory bowel disease (IBD) in mice more effectively than common FDA-approved medications. IBD is an umbrella term for chronic debilitating and sometimes fatal diseases like ulcerative colitis and Crohn's, which are characterized by inflammation in the digestive tract.
An official website of the United States government.